Skip to main content
main-content

04-12-2018 | Oncology | Video

Prophylactic treatment with rivaroxaban reduces cancer patients' VTE risk

Study author Alok Khorana discusses the results of the CASSINI trial, demonstrating a reduction in venous thromboembolism during treatment with rivaroxaban among patients with cancer (2:54).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

image credits